We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vascular Effect of Tibolone Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01679795
First Posted: September 6, 2012
Last Update Posted: April 3, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Selmo Geber, Federal University of Minas Gerais
September 3, 2012
September 6, 2012
April 3, 2015
February 2012
February 2015   (Final data collection date for primary outcome measure)
Flow-mediated dilation of the brachial artery one month after treatment started Flow-mediated dilation of the brachial artery one month after treatment started Flow-mediated dilation of the brachial artery [ Time Frame: 30 days ]
Flow-mediated dilation will be measured by high resolution ultrasound
Same as current
Complete list of historical versions of study NCT01679795 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vascular Effect of Tibolone Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery
Not Provided
The aim of this study is to evaluate the vascular effects of tibolone on climateric women measured by flow-mediated evaluation of the brachial artery using high resolution ultrasound and compare to placebo.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Flow-mediated Dilation Evaluation of the Brachial Artery
  • Drug: Tibolone
    Other Name: Livial
  • Drug: Placebo
  • Experimental: Tibolone
    patientes will use tibolone 2,5mg/day during 30 days
    Intervention: Drug: Tibolone
  • Placebo Comparator: Placebo use
    Patients will use placebo for 30 days
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
February 2015
February 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women without menstrual cycles whithin the last 12 months and FSH>30IU/L
  • Healthy women
  • Women that were not using drugs with potential vascular effect whithin the last 1 year
  • Women that never used hormone replacement therapy

Exclusion Criteria:

  • Smoking
  • Blood Pressure > 160/90 mm Hg.
  • Breast and or endometrial cancer
  • History of acute myocardial infarction
  • Diabetes
  • Vaginal bleeding of any origin
  • Hepatic disease
  • thrombophlebitis or thromboembolic disorders
Sexes Eligible for Study: Female
50 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Brazil
 
 
NCT01679795
TDILA
Not Provided
Not Provided
Not Provided
Selmo Geber, Federal University of Minas Gerais
Federal University of Minas Gerais
Not Provided
Not Provided
Federal University of Minas Gerais
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP